Affiliation:
1. Indira Gandhi Government General Hospital & Post Graduate Institute, Pondicherry, India
2. Mahatma Gandhi Medical College and Research Institute, Pillayarkuppam, Puducherry , India
Abstract
Tofacitinib, a Janus kinase (JAK) inhibitor, represents a significant advancement in the treatment of rheumatoid arthritis (RA), a chronic inflammatory disorder. This manuscript provides an in-depth review of the efficacy, safety, and clinical application of tofacitinib in RA management. Through a comprehensive analysis of clinical trials, real-world studies, and comparative assessments with other RA therapies, we aim to elucidate the role of tofacitinib in improving patient outcomes. The review highlights the mechanisms of action, clinical efficacy, safety profile, and practical considerations for incorporating tofacitinib into RA treatment regimens.
Publisher
IP Innovative Publication Pvt Ltd
Reference26 articles.
1. Smolen JS, Aletaha D, Mcinnes IB, Rheumatoid arthritis.Lancet 2016;388(10055):2023-38
2. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
3. Choy EH, Panayi GS, Cytokine pathways and joint inflammation in rheumatoid arthritis.N Engl J Med 2001;344(12):907-16
4. Fleischmann R, Cutolo M, Genovese MC, Sugiyama N, Yuasa H, Toyoizumi S, Tofacitinib, an oral Janus kinase inhibitor, as monotherapy in patients with active rheumatoid arthritis: results from the ORAL Solo trial.Ann Rheum Dis 2012;71(12):1895-902
5. D Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, C Zerbini, Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: results from a phase III randomized, placebo-controlled trial.Arthritis Rheum 2013;65(3):559-70